GCM
DYN icon

Graham Capital Management’s Dyne Therapeutics DYN Stock Holding History

Graham Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,172
Closed -$239K – 1317
2026
Q1 		$239K Sell
13,172
-22,995
-64% -$397K 0.01% 900
2025
Q4 		$707K Sell
36,167
-7,009
-16% -$133K 0.02% 495
2025
Q3 		$546K Buy
43,176
+29,688
+220% +$339K 0.01% 581
2025
Q2 		$128K Sell
13,488
-48,781
-78% -$537K ﹤0.01% 1186
2025
Q1 		$651K Buy
+62,269
New +$891K 0.01% 697
2024
Q3 		– Sell
-6,618
Closed -$234K – 1150
2024
Q2 		$234K Sell
6,618
-11,778
-64% -$342K 0.01% 815
2024
Q1 		$522K Buy
+18,396
New +$416K 0.01% 616

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Graham Capital Management's DYN Position: Q2 2026 in Review

Graham Capital Management sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 13,172 shares — an estimated $239K sold.

Graham Capital Management first reported a position in DYN in Q1 2024 and held it in 7 quarters. The position peaked at $707K in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Graham Capital Management reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 13,172 Dyne Therapeutics shares in Q2 2026, an estimated $239K.
  • Graham Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and held it in 7 quarters.
  • Graham Capital Management's Dyne Therapeutics position peaked at $707K in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.